Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal

You know him, right? that it R.It is from the next generation of Enehealth Startup, which is famous for taking eye connection from erectile dysfunction.

Of course, the bedroom pills are not all from the seller. Uberized men’s health application also provides a treatment for hair loss, meds std, mental health services, and GLP-1 weight loss treatments-although this is now disappearing.

The year 2024 was supported by global demand and slow production, in GLP-1. It is originally used to treat type 2 diabetes, GLP-1 rodes such as slow digestion in Semaglutide and Tirzepatide and gives users a feeling of fullness after eating less. Display problems recently began to reduce late 2024, when the compound sepycats began to be patented like OzemPIC and Zepbound – to dump the market when the FDA (FDA) temporarily stopped some regulations.

Quickly a few months forward, and these food and drug administration regulations have returned in full swing, as well as the court rulings that may end the copy market forever. This is bad news for Jz, which boasted that it brought cold revenues worth $ 225 million in 2024, with an estimated $ 725 million in weight -revenue on the road in 2025.

With all this money on the line, HIMS decided to launch a new courageous strategy to combat federal regulations: E-Begging.

Although the general Hims for Viagra ads are not new, users on Facebook and Instagram may now lead the ads after that call to work: “

Rest. You will fill the form to send a message directly to the US Food, Drugs and congress Department on behalf of him.

“I ask you to think about the real variable effect of life for these treatments,” says the message before baked goods. “Please make sure that patients continue to reach the compound GLP-1 as a decisive part of the health management. I hope that the administration will listen to the voices of those who support this medicine and depend on this medicine.”

Although it may be, the company has a point. GLP-1 is sold by HIMS and remote healthcare platforms for a small part of the brand’s costs. HIMS currently offers compound parking at $ 165 per month – compared to $ 1,799 per month for OzemPic, and $ 1999 for Wegovy.

But solving the problem will be complicated, at the very least. Although patent patent companies and their pressure groups have gone against the compound GLP-1 with a variety of excuses-the least of which is not that the imitation lacks the approval of the FDA-companies like HIMS were not exactly about what is in its mixture, too.

Others argue that American taxpayers have already paid their way, as the federal government spent $ 6.2 billion on GLP-1 research for weight loss-a profitable industry now reaches tens of dollars.

It is a difficult and difficult road. Certainly, the normal factor cannot afford brand products, although the GLP-1 vehicle leaves something required in the transparency section. As, the highest votes in the room are the most gaining players – the least lost.

More about medicines: Food and Drug Administration (FDA